The Technical Analyst
Prophase Labs Inc [PRPH]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Prophase Labs Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.02% $4.90
America/New_York / 26 apr 2024 @ 13:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 88.42 mill |
| EPS: | -0.980 |
| P/E: | -5.00 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 18.05 mill |
| Avg Daily Volume: | 0.0515 mill |
| RATING 2024-04-26 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.00 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -5.00 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.52 - 5.23 ( +/- 7.26%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-17 | Karkus Ted William | Buy | 400 000 | Option (right to buy) |
| 2024-01-01 | Latkin Jed | Buy | 500 000 | Option (right to buy) |
| 2024-01-01 | Latkin Jed | Buy | 0 | |
| 2024-03-17 | Hirsch Warren | Buy | 70 000 | Option (right to buy) |
| 2024-03-17 | Gleckel Louis Md | Buy | 70 000 | Option (right to buy) |
| INSIDER POWER |
|---|
| 17.96 |
| Last 98 transactions |
| Buy: 8 777 863 | Sell: 8 858 292 |
Forecast:
14:43 - $4.78
Live Trading Signals (every 1 min)
Forecast
1: 13:13 - $4.88
Forecast 2: 14:03 - $4.84
Forecast 3: 14:43 - $4.78
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.90 (-1.02% ) |
| Volume | 0.0335 mill |
| Avg. Vol. | 0.0515 mill |
| % of Avg. Vol | 65.02 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PRPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PRPH
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Latest Press Releases
2024-04-25 08:00:00 - Press Release
Prophase Labs To Present At The Planet Microcap Showcase: Vegas 2024 On Wednesday, May 1, 2024 & 1x1 Meetings On Thursday, May 2, 2024
Garden city, ny, april 25, 2024 (globe newswire) -- prophase labs, inc. (nasdaq: prph), a biopharma, genomics and diagnostics company, today announced that it will be presenting at the planet microcap showcase: vegas 2024 on wednesday, may 1, 2024 at 11:30 am pst, 2:30 pm est. ted karkus, ceo, will be hosting the presentation and answering questions at the conclusion.
2024-04-16 08:00:00 - Press Release
Prophase Labs Unveils Project Zenq-ai
Leveraging prophase labs' ai platform, massive genomics database and patented esophageal cancer insights for antibody drug conjugates development.
2024-04-15 08:29:50 - Press Release
Prism Marketview – Biotech Breakfast
Mobile-health network solutions (mndr) ipos; q32 bio surges; ema concludes glp-1 drugs not associated with suicidal thoughts new york, n.y., april 15, 2024 – prism marketview – healthcare equities finished lower on friday, in line with broad declines across the market.
2024-04-10 08:00:00 - Press Release
Prophase Labs Seeks To Transform Esophageal Cancer Detection And Management With Launch Of Its Be-smart Test In H2 2024
Garden city, ny, april 10, 2024 (globe newswire) -- prophase labs, inc. (nasdaq: prph) (“prophase” or the “company”), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough be-smart test for esophageal cancer. the company is aiming for commercial launch in the second half of 2024.
2024-04-01 21:00:00 - Press Release
Prophase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Garden city, ny, april 01, 2024 (globe newswire) -- prophase labs, inc. (nasdaq: prph) (“prophase” or the “company”), a next-generation biopharma, genomics, and diagnostics company, today announced that it has granted an inducement stock option to purchase up to 50,000 shares of the company's common stock to lance bisesar, who recently joined the company as controller. this award was made in accordance with the employment inducement award exemption provided by nasdaq rule 5635(c)(4) and was therefore not awarded under the company's stockholder approved equity plan. the option award will vest as follows, contingent upon continued service: 25% will vest on each of the next four anniversaries of the grant date...
Latest News
2024-04-25 08:00:00 - GlobeNewsWire
ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
Garden City, NY, April 25, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a biopharma, genomics and diagnostics Company, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11:30 am PST, 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation and answering questions at the conclusion.
2024-03-15 17:45:21 - Seeking Alpha
ProPhase Labs, Inc. (PRPH) Q4 2023 Earnings Call Transcript
2024-03-08 08:00:00 - GlobeNewsWire
PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024
GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted by Renmark Financial on March 15, 2024 at 11:00 am EDT. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
2023-11-09 16:11:02 - Seeking Alpha
ProPhase Labs, Inc. (PRPH) Q3 2023 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2023 Earnings Conference Call November 9, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Yi Chen - H.C. Wainwright Hunter Diamond - Diamond Equity Dennis Waldman - Barrett Productions Operator Good day and welcome the ProPhase Labs Incorporated Third Quarter 2023 Financial Results and Corporate Update.
2023-10-12 08:00:00 - GlobeNewsWire
ProPhase Labs to Present at The ThinkEquity Conference
GARDEN CITY, NY, Oct. 12, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today announced it will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York.
2023-08-12 11:04:08 - Seeking Alpha
ProPhase Labs, Inc. (PRPH) Q2 2023 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q2 2023 Earnings Conference Call August 10, 2023 11:00 AM ET Company Participants Ted Karkus - Chairman and CEO Conference Call Participants Adam Waldo - Lismore Partners Dennis Waldman - Barrett Productions Yi Chen - H.C. Wainwright Operator Good day, and welcome to the ProPhase Labs Second Quarter 2023 Financial Results and Corporate Update.
2023-08-10 10:40:00 - GlobeNewsWire
ProPhase Labs Announces Updated Conference Call Dial-in Information for Thursday August 10, 2023 at 11:00 a.m. Eastern Time for Second Quarter 2023 Financial Results Call.
Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) Conference Call and Webcast Details Management will host a conference call at 11:00 AM ET, Thursday, August 10, 2023, to provide an update on corporate developments and review financial results. Following management's formal remarks, there will be a question-and-answer session.
2023-08-02 08:00:00 - GlobeNewsWire
ProPhase Labs to Host Second Quarter 2023 Financial Results Conference Call on Thursday, August 10, 2023 at 11:00 a.m. Eastern Time
GARDEN CITY, NY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on Thursday, August 10, 2023, at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30, 2023 and provide a business update. A press release detailing these results will be issued prior to the call.
2023-06-30 09:44:00 - Market Watch
Navidea Biopharmaceuticals rejects ProPhase Labs offer
Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navidea and is not in the best interest of shareholders. ProPhase, a biotech, genomics and diagnostics company, said in a release Thursday that on June 8 it had offered $7 million in cash or $9.1 million in common stock for the assets, with the cash offer equivalent to over two times the then-current market cap of Navidea.
2023-06-11 01:16:11 - Seeking Alpha
ProPhase Labs Continues To Make The Right Moves - Reiterate Strong Buy
ProPhase Labs thrived in the Covid era and then wisely used the gains to invest in new testing capabilities including whole genome sequencing and a new esophageal cancer test. The capabilities will allow PRPH to greatly increase its currently addressable market, and, if all goes well, within a year and a half revenues should start expanding precipitously. PRPH's finances and operational experience should enable it to get to the developmental finish line without needing to execute any dilutive financings.